Pharma dealmaking for drugs invented in China is putting pressure on U.S. biotechs to compete harder, according to investors ...
Novo sells semaglutide as Ozempic and Rybelsus for diabetes and as Wegovy for obesity. In price talks, CMS will treat the ...
Announcement of the 15 medicines chosen for the second round of negotiations is one of the Biden administration’s final ...
Intra-Cellular has had success selling Caplyta, a brain-rebalancing drug that's approved to treat schizophrenia and bipolar ...
While Biogen has made an opportunistic bid for partner Sage, its top executive seemed to play down the urgency for his ...
A high-dose form of Novo’s obesity drug led to 20% weight loss over 72 weeks. Meanwhile, Atara got a complete response letter ...
Roche's core research spans five large areas. Boris Zaïtra, who now leads corporate business development, is confident his ...
Drug executives talked M&A and the incoming administration, but also weighed the outlook for cell and gene therapy developers ...
Agency commissioners voted unanimously on Tuesday to publish the report, which makes a similar attack on the drug middlemen ...
Analysts say the deal, which would give Biogen full control over the drug Zurzuvae, could be a smart financial move. Yet it's ...
The biotech plans to use the funding to advance clinical testing of an epigenetic silencing therapy it hopes could treat ...
Regenxbio, a prolific developer of gene therapy technology, will hand Japan’s Nippon Shinyaku certain rights to two ...